Are adverse effects incorporated in economic models? A survey of current practice

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 3, 2010, Pages 323-329

  Craig, Dawn ^a   McDaid, Catriona ^a   Fonseca, Tiago ^a   Stock, Christian ^a   Duffy, Steven ^a   Woolacott, Nerys ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Adverse effects events; Cost effectiveness analysis; Decision analytic models; Decision modeling; Economic models; Health technology assessment research

Indexed keywords

ADVERSE EFFECTS/EVENTS; COST-EFFECTIVENESS ANALYSIS; DECISION MODELING; DECISION-ANALYTIC MODELS; ECONOMIC MODELS; HEALTH TECHNOLOGY ASSESSMENT RESEARCH;

COST EFFECTIVENESS; COSTS; ECONOMIC ANALYSIS; ENGINEERING RESEARCH; HEALTH; MATHEMATICAL MODELS; RATING; SURVEYS; TECHNOLOGY;

COST BENEFIT ANALYSIS;

ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH PROGRAM; HEALTH SURVEY; MEDICAL RESEARCH; STATISTICAL MODEL; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; ECONOMICS; INFORMATION PROCESSING; METHODOLOGY; REVIEW; SENTINEL SURVEILLANCE; UNITED STATES;

COST-BENEFIT ANALYSIS; DATA COLLECTION; MODELS, ECONOMIC; SENTINEL SURVEILLANCE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 78049435678     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462310000371     Document Type: Article

References (26)

1. Asscher AW, Parr GD, Whitmarsh VB. Towards the safer use of medicines. BMJ. 1995;311:1003-1006.
2. Bernal-Delgado E, Fisher E. Abstracts in high profile journals often fail to report harm. BMC Med Res Methodol. 2008;8:14.
3. Clark W, Jobanputra P, Barton P, et al. The clinical and costeffectiveness of anakinra for the treatment of rheumatoid arthritis in adults:Asystematic reviewand economic analysis. Health Technol Assess. 2004;8:1-105.
4. Cooper N, Coyle D, Abrams K, et al. Use of evidence in economic decision models: An appraisal of health technology assessments in the UK since 1997. XIII Cochrane Colloquium; October 22-26, 2005; Melbourne, Australia. [Abstract 37].
5. CooperN,Coyle D, Abrams K, et al.Use of evidence in decision models: An appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy. 2005;10:245-250.
6. Cuervo GL, Clarke M. Balancing benefits and harms in health care. BMJ. 2003;327:65-66.
7. Davies L, Brown TJ, Haynes S, et al. Cost-effectiveness of cell salvage and alternativemethods of minimising perioperative allogeneic blood transfusion: A systematic review and economic model. Health Technol Assess. 2006;10:1-210.
8. Dretzke J, Cummins C, Sandercock J, et al. Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus. Health Technol Assess. 2004;8:1-183.
9. Drummond M, Iglesias C, Cooper N. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: A game of two halves? Int J Technol Assess Health Care. 2008;24:146-150.
10. Ernst E, Pittler MH. Assessment of therapeutic safety in systematic reviews: Literature review. BMJ. 2001;323:546.
11. Garside R, Pitt M, Somerville M, et al. Surveillance of Barrett's oesophagus: Exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess. 2006;10:1-142.
12. Goodacre S, Sampson F, Stevenson M, et al. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technol Assess. 2006;10.
13. Hartwell D, Colquitt J, Loveman E, et al. Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: Systematic review and economic evaluation. Health Technol Assess. 2005;9:1-99.
14. Hopewell S, Wolfenden L, Clarke M. Reporting of adverse events in systematic reviews can be improved: Survey results. J Clin Epidemiol. 2008;61:597-602.
15. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess. 2006;10:iii-iv.
16. Main C, Bojke L, Griffin S, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: A systematic review and economic evaluation. Health Technol Assess. 2006;10:1-292.
17. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
18. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8:1-158.
19. Rovira J, Antonanzas F. Economic analysis of health technologies and programmes: A Spanish proposal for methodological standardisation. Pharmacoeconomics. 1995;8:245-252.
20. Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha- 2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 2004;8:1-125.
21. Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006;42:2867-2875.
22. Thomas J, Brunton J. EPPI-Reviewer 3.0: Analysis and management of data for research synthesis. EPPI-Centre software. London: Social Science Research Unit, Institute of Education. 2006.
23. Wardlaw JM, Chappell FM, Stevenson M, et al. Accurate, practical and cost-effective assessment of carotid stenosis in the UK. Health Technol Assess. 2006;10:1-182.
24. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on good research practices-modeling studies. Value Health. 2003;6:9-17.
25. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: A systematic review. Health Technol Assess. 2006;10:1-252.
26. Yao G, Albon E, Adi Y, et al. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. Health Technol Assess. 2006;10:1-157.